Alison Crawford, PhDSenior Staff Scientist, Oncology and Angiogenesis at Regeneron Pharmaceuticals
Dr. Alison Crawford is a Senior Staff Scientist in the immune-oncology group at Regeneron Pharmaceuticals, Inc. She has >18 years of immunology research experience, including > 8 years in the pharmaceutical industry. At Regeneron Pharmaceuticals, her team is responsible for IND-enabling studies as well as mechanistic studies using bispecific antibodies for oncology indications. She led the in vivo pre-clinical research efforts on REGN4018 (MUC16xCD3) to advance the antibody through to IND submission. Dr. Crawford completed her BSc in Immunology from Glasgow University before being admitted to the Wellcome Trust Ph.D. program at Edinburgh University where she focused on T cell memory. Her post-doctoral work at the University of Pennsylvania examined T cell exhaustion during chronic viral infection and the use of checkpoint blockade to alleviate this exhaustion.